基于生态位适宜度的中国生物医药产业集聚测度研究

目的/意义 生物医药产业是中国生物产业的发展龙头，研究生物医药产业的分布状况，对于促进生物医药产业集聚发展具有重要意义。 方法/过程 选取产业政策、产业基础和产业技术资源三类指标，并选取我国31个省(自治区/直辖市)为样本，建立模型测算其生物医药产业的生态位适宜度，同时对其结果进行SPSS聚类分析。 结果/结论 从纵向来看，大部分地区近6年的生物医药产业发展较为稳定，尤其是东部的山东和江苏地区; 从横向来看，据生态位值可分为不同的发展类型，生物医药产业呈集聚发展，并且生态位值越高的区域，生物医药产业的生存和抗变能力越强，其发展能力也就越好。进而，针对我国生物医药产业的集聚发展提出了增强创新能力、完善政策体系、培育龙头企业、提高集聚效应、提升国际合作等建议。

Study on Measurement of China's Biomedical Industry Agglomeration Based on Niche Suitability

Purpose /Significance The bio-pharmaceutical industry is the leader in the development of China's bio-pharmaceutical industry. Studying the distribution of bio-pharmaceutical industry is of great significance for promoting the agglomeration and development of bio-pharmaceutical industry. Method /Process Three indicators of industrial policy, industrial base and industrial technology resources are selected, and 31 provinces (autonomous regions/municipalities directly under the central government) aretaken as samples to establish a model to measure the niche suitability of bio-pharmaceutical industry, and the results have beenstudied by SPSS cluster analysis. Result/Conclusion The results show that from a longitudinal perspective, the bio-pharmaceutical industry in most regions has been developing steadily in the last six years, especially in the eastern Shandong and Jiangsu regions. From the horizontal point of view, the niche value can be divided into different types of development. The industry is clustered and developed, and the higher the niche value is, the stronger the survival and resilience of the bio-pharmaceutical industry is, and the better its development capability is. Furthermore, in response to the development of bio-pharmaceutical industry in China, the paper proposes strategies for enhancing innovation capabilities, improving policy systems, fostering leading enterprises, increasing agglomeration effects, and enhancing international cooperation.